IL249587A0 - Heterocyclic carboxylic acids as activators of soluble guanylate cyclase - Google Patents
Heterocyclic carboxylic acids as activators of soluble guanylate cyclaseInfo
- Publication number
- IL249587A0 IL249587A0 IL249587A IL24958716A IL249587A0 IL 249587 A0 IL249587 A0 IL 249587A0 IL 249587 A IL249587 A IL 249587A IL 24958716 A IL24958716 A IL 24958716A IL 249587 A0 IL249587 A0 IL 249587A0
- Authority
- IL
- Israel
- Prior art keywords
- quanylate
- cyclase
- activators
- soluble
- carboxylic acids
- Prior art date
Links
- 101710095468 Cyclase Proteins 0.000 title 1
- -1 Heterocyclic carboxylic acids Chemical class 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462027376P | 2014-07-22 | 2014-07-22 | |
| PCT/US2015/041245 WO2016014463A1 (en) | 2014-07-22 | 2015-07-21 | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL249587A0 true IL249587A0 (en) | 2017-02-28 |
Family
ID=53783363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL249587A IL249587A0 (en) | 2014-07-22 | 2016-12-15 | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9353090B2 (https=) |
| EP (1) | EP3172202B1 (https=) |
| JP (1) | JP6602840B2 (https=) |
| KR (1) | KR20170035993A (https=) |
| CN (1) | CN106459017B (https=) |
| AP (1) | AP2016009615A0 (https=) |
| AR (1) | AR101265A1 (https=) |
| AU (1) | AU2015292833B2 (https=) |
| BR (1) | BR112017000943A2 (https=) |
| CA (1) | CA2955937A1 (https=) |
| CL (1) | CL2017000071A1 (https=) |
| CO (1) | CO2017000438A2 (https=) |
| DK (1) | DK3172202T3 (https=) |
| EA (1) | EA032972B1 (https=) |
| ES (1) | ES2784477T3 (https=) |
| HU (1) | HUE049231T2 (https=) |
| IL (1) | IL249587A0 (https=) |
| MX (1) | MX378717B (https=) |
| PE (1) | PE20170249A1 (https=) |
| PH (1) | PH12017500111A1 (https=) |
| PL (1) | PL3172202T3 (https=) |
| PT (1) | PT3172202T (https=) |
| SG (2) | SG11201700507XA (https=) |
| TW (1) | TWI711615B (https=) |
| UY (1) | UY36226A (https=) |
| WO (1) | WO2016014463A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018015718A2 (pt) | 2016-02-01 | 2019-01-08 | Ironwood Pharmaceuticals Inc | utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash) |
| KR102456406B1 (ko) | 2016-09-14 | 2022-10-19 | 게노마티카 인코포레이티드 | 1,3-지방 디올 화합물 및 그 유도체 |
| CA3039735A1 (en) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Combination containing sgc activators and mineralocorticoid receptor antagonists |
| CN106495999B (zh) * | 2016-10-18 | 2019-08-16 | 亳州学院 | 一种芳香醛及其合成方法 |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| US20200392158A1 (en) | 2017-07-14 | 2020-12-17 | Glaxosmithkline Intellectual Property Development Limited | Inhibitors of leucine rich repeat kinase 2 |
| EP3668834B1 (en) * | 2017-08-17 | 2024-10-02 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| US20210230155A1 (en) * | 2018-04-27 | 2021-07-29 | Hetero Labs Limited | Process for preparation of ((3r,11br)-1,3,4,6,7,11b-hexahydro-9,10-di(methoxy-d3)-3-(2-methylpropyl)-2h-benzo[a]quinolizin-2-one |
| JP7314173B2 (ja) | 2018-04-30 | 2023-07-25 | バイエル アクチェンゲゼルシャフト | 認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用 |
| CA3100096A1 (en) | 2018-05-15 | 2019-11-21 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
| EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
| JP7543259B2 (ja) | 2018-10-18 | 2024-09-02 | アクイタス セラピューティクス インコーポレイテッド | 活性剤の脂質ナノ粒子送達のための脂質 |
| EA202191554A1 (ru) | 2018-12-03 | 2021-09-02 | Фмк Корпорейшн | Способ получения n-фенилпиразол-1-карбоксамидов |
| EP3911675A1 (en) | 2019-01-17 | 2021-11-24 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| WO2022016070A1 (en) | 2020-07-16 | 2022-01-20 | Acuitas Therapeutics, Inc. | Cationic lipids for use in lipid nanoparticles |
| CN114957087A (zh) * | 2022-04-13 | 2022-08-30 | 湖南复瑞生物医药技术有限责任公司 | 一种帕罗韦德中间体制备方法 |
| EP4536205A1 (en) | 2022-06-09 | 2025-04-16 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
| CN117384082A (zh) * | 2022-07-20 | 2024-01-12 | 杭州国瑞生物科技有限公司 | 一种6,6-二甲基-3-氮杂双环[3.1.0]己烷的合成方法 |
| WO2024097316A1 (en) | 2022-11-04 | 2024-05-10 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators for treating systemic sclerosis |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002026712A2 (en) | 2000-09-29 | 2002-04-04 | Millennium Pharmaceuticals, Inc. | Quaternary amines and related inhibitors of factor xa |
| BRPI0614001A2 (pt) | 2005-07-18 | 2011-03-01 | Bayer Healthcare Ag | uso de ativadores e estimuladores de guanilato ciclase solúvel para a prevenção ou tratamento de distúrbios renais |
| US20080045560A1 (en) | 2006-08-15 | 2008-02-21 | Wyeth | Pyrrolidine and related derivatives useful as PR modulators |
| WO2008138483A1 (en) | 2007-05-12 | 2008-11-20 | Bayer Schering Pharma Aktiengesellschaft | sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS |
| KR20100059952A (ko) | 2007-09-06 | 2010-06-04 | 머크 샤프 앤드 돔 코포레이션 | 가용성 구아닐레이트 사이클라제 활성제 |
| CN101815514B (zh) | 2007-10-05 | 2012-05-09 | 塞诺菲-安万特德国有限公司 | 磺酰基取代的2-磺酰基氨基苯甲酸n-苯基酰胺在治疗疼痛中的应用 |
| WO2009068652A1 (en) | 2007-11-30 | 2009-06-04 | Smithkline Beecham Corporation | 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators |
| PE20091258A1 (es) | 2007-12-03 | 2009-09-12 | Smithkline Beecham Corp | Derivados de piridina como activadores de la guanilato ciclasa soluble |
| CN102056907B (zh) | 2008-04-04 | 2014-12-31 | 武田药品工业株式会社 | 杂环衍生物及其用途 |
| WO2010015652A2 (en) | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Thiazole compounds as activators of soluble guanylate cyclase |
| WO2010015653A1 (en) | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Pyrimidine derivatives as activators of soluble guanylate cyclase |
| AU2009322836B2 (en) | 2008-11-25 | 2013-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| EP2387404B1 (en) | 2009-01-17 | 2014-06-25 | Bayer Intellectual Property GmbH | Sgc stimulators and activators in combination with pde5 inhbitors for the treatment of erectile dysfunction |
| CN102414194A (zh) | 2009-02-26 | 2012-04-11 | 默沙东公司 | 可溶性鸟苷酸环化酶激活剂 |
| WO2011095553A1 (en) | 2010-02-05 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft | Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction |
| SI2531187T1 (sl) | 2010-02-05 | 2016-01-29 | Adverio Pharma Gmbh | Stimulatorji sGC ali aktivatorji sGC sami in v kombinaciji z inhibitorji PDE5 za zdravljenje cistične fibroze |
| SI2576548T1 (sl) | 2010-05-26 | 2015-11-30 | Adverio Pharma Gmbh | Uporaba sGC stimulatorjev, sGC aktivatorjev, samih in v kombinacijah s PDE5 inhibitorji za zdravljenje sistemske skleroze |
| EP2687210A1 (de) | 2010-06-25 | 2014-01-22 | Bayer Intellectual Property GmbH | Verwendung von Stimulatoren und Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Sichelzellanämie und Konservierung von Blutersatzstoffen |
| EP2632551B1 (en) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| JP5715713B2 (ja) * | 2011-03-10 | 2015-05-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性グアニル酸シクラーゼ活性化因子 |
| JP5826393B2 (ja) | 2011-08-12 | 2015-12-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性グアニル酸シクラーゼ活性化因子 |
| EP2594270A3 (en) | 2011-11-18 | 2013-07-31 | BIP Patents | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
| ES2748798T3 (es) * | 2012-09-07 | 2020-03-18 | Boehringer Ingelheim Int | Alcoxi pirazoles como activadores de la guanilato ciclasa soluble |
| WO2015095515A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Sgc activators for the treatment of glaucoma |
-
2015
- 2015-07-21 EP EP15747311.7A patent/EP3172202B1/en active Active
- 2015-07-21 CA CA2955937A patent/CA2955937A1/en not_active Abandoned
- 2015-07-21 AR ARP150102304A patent/AR101265A1/es unknown
- 2015-07-21 CN CN201580033515.4A patent/CN106459017B/zh active Active
- 2015-07-21 EA EA201790246A patent/EA032972B1/ru not_active IP Right Cessation
- 2015-07-21 WO PCT/US2015/041245 patent/WO2016014463A1/en not_active Ceased
- 2015-07-21 AU AU2015292833A patent/AU2015292833B2/en not_active Ceased
- 2015-07-21 US US14/804,363 patent/US9353090B2/en active Active
- 2015-07-21 TW TW104123596A patent/TWI711615B/zh not_active IP Right Cessation
- 2015-07-21 PE PE2017000087A patent/PE20170249A1/es unknown
- 2015-07-21 SG SG11201700507XA patent/SG11201700507XA/en unknown
- 2015-07-21 BR BR112017000943A patent/BR112017000943A2/pt not_active Application Discontinuation
- 2015-07-21 ES ES15747311T patent/ES2784477T3/es active Active
- 2015-07-21 DK DK15747311.7T patent/DK3172202T3/da active
- 2015-07-21 PL PL15747311T patent/PL3172202T3/pl unknown
- 2015-07-21 PT PT157473117T patent/PT3172202T/pt unknown
- 2015-07-21 JP JP2017503554A patent/JP6602840B2/ja active Active
- 2015-07-21 SG SG10201806565SA patent/SG10201806565SA/en unknown
- 2015-07-21 KR KR1020177004761A patent/KR20170035993A/ko not_active Withdrawn
- 2015-07-21 HU HUE15747311A patent/HUE049231T2/hu unknown
- 2015-07-21 MX MX2017000926A patent/MX378717B/es unknown
- 2015-07-21 AP AP2016009615A patent/AP2016009615A0/en unknown
- 2015-07-22 UY UY0001036226A patent/UY36226A/es unknown
-
2016
- 2016-12-15 IL IL249587A patent/IL249587A0/en unknown
-
2017
- 2017-01-11 CL CL2017000071A patent/CL2017000071A1/es unknown
- 2017-01-18 PH PH12017500111A patent/PH12017500111A1/en unknown
- 2017-01-19 CO CONC2017/0000438A patent/CO2017000438A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL249587A0 (en) | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase | |
| CY1125496T1 (el) | 3-υποκατεστατημενα προπιονικα οξεα ως αναστολεις αλφα v ιντεγκρινης | |
| PT3464272T (pt) | Novos derivados heterocíclicos úteis como inibidores de shp2 | |
| IL247970A (en) | Quinoline history as smo inhibitors | |
| HUE041926T2 (hu) | IRAK4 inhibitor biciklusos heterociklilszármazékok | |
| IL254898A0 (en) | History of quinolines as tam rtk inhibitors | |
| HUE040274T2 (hu) | Heteroarilamidok a proteinaggregáció inhibitoraiként | |
| DK3201206T3 (da) | Borsyrederivater | |
| IL246345A0 (en) | History of 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid as neprilysin inhibitors | |
| IL249674A0 (en) | Quinolizinone derivatives as pi3k inhibitors | |
| FR3023290B1 (fr) | Derives de flavaglines | |
| DK3143018T3 (da) | Carboxamidderivater | |
| PL3200786T3 (pl) | Zastosowanie pochodnych pirydylowych o skondensowanym układzie bicyklicznym jako inhibitorów fgfr4 | |
| PT3134396T (pt) | Derivados de amino piridina como inibidores da fosfatidilinositol 3-quinase | |
| LT3319970T (lt) | Pirido-oksazinono dariniai kaip tnap inhibitoriai | |
| HUE042119T2 (hu) | Aminoészter-származékok | |
| IL266121A (en) | A history of metamorphosed quinoxaline as an inhibitor of pfkfb | |
| IL251099A0 (en) | A salt of phenylglycine methyl ester | |
| DK3283066T3 (da) | 4-Phenylsmørsyrederivater | |
| HK1232872A1 (en) | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase | |
| TH1501006974A (th) | อนุพันธ์เฮเทอโรไซคลิค | |
| TH1501004620A (th) | เฮทเทอโรไซคลิก เอไมด์ ในรูปสารยับยั้งไคเนส | |
| TH1501007053A (th) | เอสเทอร์ของกรดโอลิโก-ไฮดรอกซิคาร์บอกซิลิกและการใช้ของมัน |